Identification of a Metabolizing Enzyme in Human Kidney by Proteomic Correlation Profiling

Hidetaka Sakurai‡, Kazuishi Kubota‡¶, Shin-ichi Inaba§, Kaoru Takanaka§, and Akira Shinagawa‡

Molecular identification of endogenous enzymes and biologically active substances from complex biological sources remains a challenging task, and although traditional biochemical purification is sometimes regarded as outdated, it remains one of the most powerful methodologies for this purpose. While biochemical purification usually requires large amounts of starting material and many separation steps, we developed an advanced method named “proteomic correlation profiling” in our previous study. In proteomic correlation profiling, we first fractionated biological material by column chromatography, and then calculated each protein’s correlation coefficient between the enzyme activity profile and protein abundance profile determined by proteomics technology toward fractions. Thereafter, we could choose possible candidates for the enzyme among proteins with a high correlation value by domain predictions using informatics tools. Ultimately, this streamlined procedure requires fewer purification steps and reduces starting materials dramatically due to low required purity compared with conventional approaches. To demonstrate the generality of this approach, we have now applied an improved workflow of proteomic correlation profiling to a drug metabolizing enzyme and successfully identified alkaline phosphatase, tissue-nonspecific isozyme (ALPL) as a phosphatase of CS-0777 phosphate (CS-0777-P), a selective sphingosine 1-phosphate receptor 1 modulator with phosphatase, tissue-nonspecific isozyme (ALPL) as a metabolizing enzyme and successfully identified alkaline phosphatase, tissue-nonspecific isozyme (ALPL) as a phosphatase of CS-0777 phosphate (CS-0777-P), a selective sphingosine 1-phosphate receptor 1 modulator with potential benefits in the treatment of autoimmune diseases including multiple sclerosis, from human kidney. We identified ALPL as a candidate protein only by the 200-fold purification and only from 1 g of human kidney. The identification of ALPL as CS-0777-P phosphatase was strongly supported by a recombinant protein, and contribution of the enzyme in human kidney extract was validated by immunodepletion and a specific inhibitor. This approach can be applied to any kind of enzyme class and biologically active substance; therefore, we believe that we have provided a fast and practical option by combination of traditional biochemical and state-of-the-art proteomic technology. Molecular & Cellular Proteomics 12: 10.1074/mcp.M112.023853, 2313–2323, 2013.

Molecular identification for an enzyme reaction or biologically active substance in an organism is challenging, although molecular biological methodologies such as expression cloning (1), recombinant protein panel (2) and RNAi screening (3) have been introduced recently as alternative approaches. Conventional biochemical purification has provided a number of successes and thus still remains a powerful, though labor-intensive strategy.

In the traditional protein purification, it had been necessary to purify an individual protein nearly to homogeneity at a microgram amount so that the purified protein could be analyzed by N-terminal amino acid sequencing. Protein identification by mass spectrometry subsequently revolutionized this technology by enabling identification of proteins at much lower abundances: individual proteins could then be associated with specific activities as soon as a band in SDS-PAGE could be observed, even when the purified protein was far from homogeneity (4–6). Although this streamlined the workflow by reducing the required starting materials as well as the separation steps for protein purification, a faster and more generalized approach from smaller starting material has still been desired because some proteins are physiochemically difficult for example in solubilization and stability. To solve these problems, we devised a proteomic correlation profiling methodology (7).

The basic concept of proteomic correlation profiling was originally developed by Andersen et al. (8). They quantitatively profiled hundreds of proteins across several centrifugation fractions by mass spectrometry and identified centrosomal proteins by calculating the correlation of these protein expression profiles with already known centrosomal proteins. In the following study, Foster et al. applied this strategy to map more than 1400 proteins to ten subcellular locations (9). Although these studies used centrifugation as a separation method and a known marker profile as a standard for correlation, we...
Enzyme Identification by Proteomic Correlation Profiling

extended this concept to use chromatography as a separation method and kinase activity as a basis for comparison; our approach successfully identified a kinase responsible for phosphorylation of peptide substrates just after one step chromatography, and was termed proteomic correlation profiling (7). Independently, Kuromitsu et al. reported identification of an active substance in the serum response element-dependent luciferase assay from interstitial cystitis urine after three-step chromatography by a similar concept (10). In theory, this general proteomic correlation profiling strategy can be adapted to any kind of separation method and activity profile but no other example has been reported thus far, therefore, actual examples where the method can be applied to other enzyme classes are required to prove its generality.

Multiple sclerosis is the most common autoimmune disorder of the central nerve system in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring (11, 12). Until recently, the standard treatments for multiple sclerosis such as interferon beta, glatiramer acetate, mitoxantrone, and natalizumab would often cause severe adverse events (13, 14), providing an opportunity for development of less dangerous treatments for this disease. However, in 2010, Food and Drug Administration approved fingolimod (Gilenya; chemical structure in Fig. 1) as the first oral medicine, and recommended this as a first-line treatment for relapsing-remitting multiple sclerosis, opening up a new therapeutic approach to the disease (15).

Sphingosine 1-phosphate receptor 1 (S1P1) modulators are emerging as a new class of drugs with potential therapeutic application in multiple sclerosis (15), and fingolimod is a nonselective sphingosine 1-phosphate (S1P) receptor modulator (16–18, 21, 22). Given its structural similarity to sphingosine, fingolimod is phosphorylated in vivo by sphingosine kinase, in particular sphingosine kinase 2 (SPHK2) (19, 20), and the fingolimod-phosphate (fingolimod-P, Fig. 1) binds to and activates four G protein-coupled S1P receptors (21, 22). By this mechanism, fingolimod-P induces internalization of S1P1 on lymphocytes, blocking the ability of the receptor to support lymphocyte egress and recirculation through secondary lymphoid organs. This suppresses immune responses and is presumably the main immunomodulatory mode of action of fingolimod.

CS-0777 (Fig. 1) is a novel selective S1P1 modulator (23). Although the immunomodulatory effects are supposed to be mainly mediated by S1P1, some lines of evidence suggest that the agonist activity on S1P receptor 3 (S1P3) could cause acute toxicity and cardiovascular deregulation, including bradycardia in rodents (24, 25). Thus, CS-0777 was designed to have more selectivity on S1P1 over S1P3 in contrast to fingolimod-P which has potent agonistic activity for S1P3, S1P4, and S1P5 in vitro (22). Like fingolimod, CS-0777 is also a prodrug phosphorylated in vivo, and the phosphorylated CS-0777 (CS-0777-P, Fig. 1) agonizes S1P1 with more than 300-fold selectivity relative to S1P3 whereas CS-0777-P has weaker effects on S1P5 and no activity on S1P2 (23). CS-0777 showed immunosuppressive activity in mice and rats, and models of experimental autoimmune encephalitis, animal models for multiple sclerosis. In healthy volunteers, single oral doses of CS-0777 caused marked, dose-dependent decreases in numbers of circulating lymphocytes, including marked and reversible decreases in circulating T and B cells (26). Furthermore, in multiple sclerosis patients, single oral doses of CS-0777 caused dose-dependent decreases in circulating lymphocytes, with a slightly greater suppression of CD4+ versus CD8+ T cells. Therefore, CS-0777 would alter immune responses solely through activation of S1P1 without S1P3 modulation in humans, which could circumvent a bradycardia adverse effect, although the relationships associating selectivity of S1P1 to S1P3 with bradycardia in humans are not fully understood (12).

Orally administered CS-0777 is phosphorylated and rapidly reaches equilibrium with CS-0777-P as in the case of fingolimod (22), suggesting that the high kinase activity in blood is balanced by phosphatases. Therefore, identification of a phosphatase, the inactivating enzyme of an active metabolite, as well as identification of a kinase, the activating enzyme of a prodrug, are critical to fully understand the mechanism of action at the molecular level for both CS-0777 and fingolimod. Sphingosine kinase 2 (SPHK2) was identified as the major kinase of fingolimod (21, 28, 29) and lipid phosphate phosphatase 3 (LPP3) was reported to be a phosphatase for fingolimod-P dephosphorylation (30), although contribution of LPP3 in vivo has not been fully studied. In our previous work, we have identified CS-0777 kinases in human blood as fructosamine 3-kinase-related protein (FN3K-RP) and fructosamine 3-kinease (FN3K) (6), whereas the phosphatase of CS-0777-P had not been identified thus far.

In this study, we have successfully identified alkaline phosphatase, tissue-nonspecific isozyme (ALPL) as the major CS-0777-P phosphatase candidate in the human kidney by proteomic correlation profiling. According to available information, this is the first report applying proteomic correlation profiling to enzyme classes other than kinases; similarly, we

---

1 The abbreviations used are: S1P1, sphingosine 1-phosphate receptor 1; ALPL, alkaline phosphatase, tissue-nonspecific isozyme; ALPI, alkaline phosphatase, intestinal; ALPP, alkaline phosphatase, placental; ALPPL, alkaline phosphatase, placental-like 2; DM, n-Dodecyl-β-D-maltopyranoside; LPP1, lipids phosphate phosphohydrolase 1; LPP2, lipid phosphate phosphohydrolase 2; LPP3, lipid phosphate phosphohydrolase 3; SPP1, spheninosine-1-phosphate phosphatase 1; SPP2, sphingosine-1-phosphate phosphatase 2; FN3K, fructosamine 3-kinase; FN3K-RP, fructosamine 3-kinease-related protein; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; LC-MS/MS, liquid chromatography equipped with tandem mass spectrometry; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; S1P, sphingosine 1-phosphate; S1P3, sphingosine 1-phosphate receptor 3; SPHK1, sphingosine kinase 1; SPHK2, sphingosine kinase 2.
believe this to be first application of proteomic correlation profiling to human tissue extract, which therefore has opened up wide usage of proteomic correlation profiling for all types of enzyme identification.

EXPERIMENTAL PROCEDURES

**Chemicals**—All chemical compounds were synthesized in Daiichi Sankyo Co., Ltd. Chemical structures are illustrated in Fig. 1.

**Human specimens**—Human frozen tissue blocks (kidney, liver, and lung) were collected by National Disease Research Interchange, and provided by the Human Animal Bridging Research Organization. The human small intestines were provided by Xenotech. Ethical approval was obtained from the Research Ethics Committee at Daiichi Sankyo Co., Ltd.

**Purification of Human Kidney CS-0777-P Phosphatase**—All purification procedures were conducted at 4 °C. The block of human kidney was minced and homogenized in 9 volumes of homogenate buffer, 0.25 M sucrose containing 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0, and protease inhibitor mixture (Complete Tablet, Roche Applied Science) using a polytron homogenizer (Kinematica). The homogenate was sonicated by a Bioruptor (COSMO BIO) and filtered by a few sheets of gauze. The tissue homogenate was centrifuged with 9000 × g for 60 min at 4 °C and the supernatant was used as S9 fraction.

The homogenate was centrifuged at 100,000 × g for 60 min, and the precipitate equivalent to 1.1 g of human kidney was dissolved in 10 ml of homogenate buffer containing 1% n-Dodecyl-β-D-maltopyranoside (DM), and then dialyzed against 1 L of anion exchange chromatography (AEX) buffer (50 mM Tris-HCl, pH 9.0, containing 0.1% DM, 5 mM CaCl2, 5 mM MgCl2, and 1 mM dithiotreitol). The dialyzed sample was filtered and loaded onto a multimodal anion exchange column (HiTrap Capto Adhere 5 ml, GE Healthcare). The column was equilibrated with AEX buffer over 30 min at a flow rate of 0–250 mM NaCl in AEX buffer for 20 min. The active fraction (1 ml) from the Mono Q column was loaded onto a gel filtration column (GFC, Superdex 200 5/50 GL, GE Healthcare). The column was equilibrated with 20 mM HEPES (pH 7.0) containing 0.1% DM, 500 mM NaCl, and 1 mM dithiotreitol (DTT) over 2 h. The separation was performed by an isocratic elution with the same buffer over 30 min at a flow rate of 40 μl/min.

**Protein Identification and Quantification by Mass Spectrometry**—Five hundred fmol of bovine serum albumin (BSA) was added as the internal standard to the fractions from the gel filtration chromatography, and then the proteins were precipitated by methanol chloroform precipitation to remove the detergent and salts (31). Briefly, four volumes of methanol, one volume of chloroform, and three volumes of water were serially added and mixed vigorously to the fractions. After centrifugation, the aqueous phase was removed and four volumes of methanol were added. The precipitated proteins were collected by centrifugation and dried completely with a centrifuge evaporator. The dried proteins were dissolved with 8 M urea, 10 mM EDTA, pH 8.0, and 10 mM DTT. The proteins were reduced at 37 °C for 20 min, followed by alkylation by incubation at 25 °C for 20 min in the dark with 20 mM iodoacetamide. The proteins were digested with 500 ng of trypsin (modified trypsin, Promega, Madison, WI) at 37 °C for 12 h. The reaction was stopped by acidification with 5% formic acid to a pH lower than 2.5. Samples were desalted and concentrated by using slightly modified Stage Tips (32) protocol.

The LTQ-Orbitrap (Thermo Fisher Scientific) was equipped with an Agilent 1100 liquid chromatography system, which was modified to have a 200–300 nL/min flow rate by an in-house flow splitter. A homemade electrospray ionization tip column (100 μm internal diameter x 150 mm length) was packed with Inertsil ODS-3 C18 (3 μm, GL Sciences). Four microliters of the sample was injected to the LC-MS/MS system, and elution of peptides was carried out with a linear gradient of acetonitrile in 0.05% formic acid to a pH lower than 2.5. Samples were desalted and concentrated by using slightly modified Stage Tips (32) protocol.

Enzyme Identification by Proteomic Correlation Profiling

![CS-0777](image1)

**CS-0777**

![CS-0777-phosphate](image2)

**CS-0777-phosphate**

![Fingolimod](image3)

**Fingolimod**

![Fingolimod-phosphate](image4)

**Fingolimod-phosphate**

**Fig. 1.** The chemical structures of CS-0777, fingolimod and their phosphorylated derivatives.
Enzyme Identification by Proteomic Correlation Profiling

Phosphatase—Entry clones of ALPL (clone number: FLJ98059AAA), alkaline phosphatase, intestinal (ALPI, FLJ93658AAA), alkaline phosphatase, placental (ALPP, FLJ69111AAA), Lidid phosphophosphorydrolase 1 (LPP1, FLJ82762AAA), lipid phosphophosphorydrolase 2 (LPP2, FLJ82497AAA), lipid phosphophosphorydrolase 3 (LPP3, FLJ92787AAA), sphenosine-1-phosphate phosphatase 1 (SPP1, FLJ94912AAA), and sphingosine-1-phosphate phosphatase 2 (SPP2, FLJ95081AAA) were obtained from the National Institute of Technology and Evaluation. Alkaline phosphatase, placental-like 2 (ALPLP, RC20430), was obtained as a C-terminal Myc-DDK (FLAG)-tagged ORF clone with the transfection-ready DNA from ORIGENE. ALPL and ALPP were expressed as fusion proteins with an N-terminal FLAG tag, and ALPL was expressed as a fusion protein of a C-terminal FLAG tag. ALPP was expressed as a fusion protein with a C-terminal Myc-FLAG tag. LPP1, LPP2, LPP3, SPP1, and SPP2 were expressed as fusion proteins with a C-terminal green fluorescence protein (GFP) tag. All proteins were expressed in human embryonic kidney 293-F cells (Invitrogen, Carlsbad, CA) with 293 fectin (Invitrogen) according to the manufacturer's protocol. The transfected cells were cultured for 72 h in Freestyle 293 Expression Medium (Invitrogen). The cells were collected by centrifugation and suspended in 10 mM HEPES, pH 7.0 containing, 0.25 mM sucrose, 1 mM DTT, and protease inhibitor mixture (Complete, Roche). After sonication, the suspensions were used as an extract.

Protein expression of ALPL, ALPI, ALPP, and ALPLP was confirmed and quantified by Western blot analysis. Proteins were loaded onto SDS-PAGE gels (4-15% gradient) and then electrotransferred onto a polyvinylidene difluoride membrane by iBlot (Invitrogen). After blocking with Aqua Block (East Coast Biologicals), the membrane was incubated with an anti-FLAG M2 antibody conjugated with horseradish peroxidase (Sigma Aldrich), with subsequent visualization by an ECL Western blot detection system (GE Healthcare). The band intensity was scanned by a NightOWL imaging system (Berthold technologies, Bad Wildbad, Germany) and quantified using C-terminal FLAG-bacterial alkaline phosphatase (Sigma Aldrich) as a standard protein. Expressed ALPs were confirmed to have phosphatase activity by using a standard substrate of p-nitrophenylphosphate (data not shown).

Protein expression of LPP1, LPP2, LPP3, SPP1, and SPP2 was confirmed and quantified by C termus fused GFP fluorescence. The cells transfected with these genes were plated at a density of 3 x 10^4 cells/well in a 96-well culture plate. Bisbenzimide H 33342 trihydrochloride (Hoechst 33342) DNA dye (Sigma) was used for staining nuclei at a final concentration of 0.01 μg/ml. GFP fluorescence of these proteins and the nuclei of all cells were visualized (magnification, 40×) with ImageXpress confocal microscopy (Molecular Devices, Sunnyvale, CA), and analyzed using MetaXpress software (Molecular Devices).

Immunodepletion of ALPL in Human Kidney Extract—DM was added to the human kidney extract at a final concentration of 0.1%, and rotated at 4 °C for 30 min. Thereafter, the extract was diluted 10-fold with TBS. Monoclonal mouse anti-ALPL antibody (sc-21708, Santa Cruz Biotechnology) or normal mouse IgG was serially diluted with PBS containing 1 mg/ml BSA. The diluted human kidney extract was incubated at 4 °C for 2 h with the diluted anti-ALPL antibody and Protein G agarose (Immunopure Plus, PIERCE) in TBS containing 200 μg/ml BSA. Subsequently, the mixture was filtered using a 0.45 μm spin top filter (Ultrafuge MC, Millipore) to remove Protein G agarose and the filtrate was tested for CS-0777-P phosphatase activity. The activity was normalized by the sample diluted by the same factor without immunodepletion.

Protein—The total protein concentration was determined by modified Bradford protein assay (Coomassie Plus Protein Assay, Thermo Fisher Scientific) or Lowry protein assay (RC DC Protein Assay Kit I, Bio-Rad Laboratories, Hercules, CA) using BSA as a standard protein. Chromatographic fractions were assayed before spike-in of BSA internal standard for label-free quantitation.
RESULTS

Fractionation and Identification of ALPL as a CS-0777-P Phosphatase Candidate—To identify the unknown phosphatase or phosphatases capable of dephosphorylating CS-0777-P in humans, we used protein correlation profiling to identify proteins that co-purified with CS-0777-P dephosphorylation activity on fractionation. At the outset of our search, it was difficult to ascertain which organs or tissues in vivo are mainly responsible for the reaction. Therefore, our strategy was first to purify an enzyme from the organ with the highest enzyme activity and identify it; second, we examined the contribution of the enzyme in the organ; third, we examined the contribution of the enzyme in the whole body. We first tested CS-0777-P phosphatase activity in the human lung, kidney, liver, and small intestine to select an appropriate starting material and found equivalent activity in these tissues (data not shown). To choose one tissue among these, we then investigated the tissues of rats and monkeys, demonstrating that the kidney had the highest activity in both species (data not shown). Therefore, we decided to use the human kidney as a purification source for this study.

The schematic diagram of this study is indicated in Fig. 2. First, we investigated the CS-0777-P phosphatase activity of kidney extract from five human specimens to assess individual variability and chose the most specimen exhibiting highest levels of enzyme activity as starting material for purification. As shown in supplemental Fig. S1, specimen #5 showed the strongest activity and thus was chosen for purification. Then, we examined biochemical characteristics for CS-0777-P phosphatase activity of the specimen, and found that: 1) the activity mainly resided in the insoluble fraction recovered after ultracentrifugation of human kidney homogenate; 2) the detergent DM effectively re-solubilized the activity; 3) activity was inactivated by EDTA, and then recovered by the addition of Ca\(^{2+}\) / Mg\(^{2+}\); 4) the activity was stable from pH 5 to pH 9; 5) the observed molecular weight of the activity was 150–170 kDa as determined by gel filtration chromatography; 6) the activity was bound to a multimodal anion exchange column (Capto adhere) at pH 9 and an anion exchange column, but was not bound to a blue dye column, hydrophobic interaction column, cation exchange column, or a hydroxyl apatite column.

We fractionated CS-0777-P phosphatase activity from 1.1 g of human kidney based on the characteristics of the enzyme described above. Because the phosphatase was in insoluble fraction, the purification was very difficult. Despite four successive steps of purification, the enzyme activity was concen-
Enzyme Identification by Proteomic Correlation Profiling

TABLE I

| Step | Protein conc. [µg/ml] | Activity [U/ml] | Volume [ml] | Total protein [mg] | Total activity [U] | Specific content [U/mg] | Step fold change | Overall fold change [%] | Step recovery [%] | Overall recovery [%] |
|------|---------------------|----------------|-------------|-------------------|-------------------|------------------------|------------------|------------------------|------------------|----------------------|
| Human kidney homogenate | 16543 | 57 | 10 | 165 | 570 | 3.4 | - | 1 | - | 100 |
| 1) Centrifugation | 4339 | 176 | 10 | 43 | 1760 | 41 | 11.8 | 12 | 309 | 309 |
| 2) Multimodal anion exchange (Capto adhere) | 188 | 18 | 5 | 0.9 | 90 | 96 | 2.4 | 28 | 51 | 16 |
| 3) Anion Exchange (Mono Q) | 101 | 42 | 1 | 0.1 | 42 | 416 | 4.3 | 121 | 47 | 7.4 |
| 4) Gel filtration (Superdex 200) | 10 | 7 | 0.05 | 0.0005 | 0.4 | 711 | 1.7 | 206 | 0.8 | 0.1 |

Fig. 3. Purification of CS-0777-P phosphatase in human kidney. Each fraction was assayed for CS-0777-P phosphatase activity and is shown as bars (left y axis). Protein concentration or UV [280 nm] are shown as lines (right y axis). A, The activity was found in 100,000 x g pellet solubilized with 1% DM. Graphs (B), (C), and (D) represent CS-0777-P phosphatase activity and protein concentration in the purification step of the first column (multimodal anion exchange chromatography) (B), the second column (anion exchange column) (C), and the third column (Gel filtration chromatography) (D). CS-0777-P phosphatase activity is shown as the average of duplicates with error bars to the minimum and maximum values (n = 2). ▼- These fraction samples were used for purification of the next step.

Although labeling-based methods provide more accurate quantitation, they also require additional experimental steps and expensive reagents. The proteins were identified and quantified by MaxQuant using an intensity-based label-free algorithm (supplemental Tables S2–S5) (33, 34, 38). After normalization by BSA, the Pearson correlation coefficients were calculated comparing CS-0777-P phosphatase activity levels with protein abundance profiles for each of the 266 identified proteins (supplemental Table S1). The highly correlated proteins were then manually evaluated based on their annotations, expression profiles, and domain structures to identify those most likely to possess the target enzyme activity. Among the top 25 most correlated proteins, ALPL was the only candidate that had a possible phosphatase domain and high correlation efficient of r = 0.9965, ranked as 2nd place among all 266 proteins (Fig. 4).

Recombinant Protein Preparation of Candidate Proteins for CS-0777-P Phosphatase—To determine whether ALPL did in
fact possess CS-0777-P phosphatase activity, we prepared a recombinant ALPL protein expressed in a mammalian overexpression system. In addition to ALPL, we prepared three other ALP isozymes, i.e. ALPI, ALPP and ALPPL, to confirm whether other ALP isoforms could dephosphorylate CS-0777-P. Furthermore, because fingolimod phosphate (fingolimod-P) was reported to be dephosphorylated by LPP3 (30), we also prepared recombinant LPP3 and other proteins close to LPP3 (LPP1, LPP2, SPP1, and SPP2) based on high amino acid sequence homology to LPP3 (39, 40) to investigate their CS-0777-P phosphatase activity.

The expression vector was transfected into a human cell line, 293-F cells. The transfected cells were homogenized and tested for CS-0777-P phosphatase activity. To estimate the expression level of the proteins, the extracts were analyzed by Western blot using an anti-FLAG antibody. Because FLAG-fused proteins migrated poorly on an SDS-PAGE gel, LPP and SPP proteins were instead quantified by GFP fluorescence using confocal microscopy (data not shown).

All four ALP isozymes showed CS-0777-P phosphatase activity (Fig. 5A). In particular, ALPL, which was identified from human kidney, had 3-fold higher specific activity compared with the other three ALP isozymes (Fig. 5A). Among the LPP and SPP proteins, only LPP3 and LPP1 showed activity, and the LPP3 had threefold higher specific activity compared with LPP1 (Fig. 5B).

Effects of ALPL Specific Inhibitor and ALPL Immunodepletion—Although recombinant LPP3 and LPP1 showed CS-0777-P phosphatase activity, we could not identify LPP3 in the purification process. Thus, to determine whether ALPL would be the major CS-0777-P phosphatase candidate in the human kidney, we examined the effects of treatment with an

**Fig. 4. Correlation between CS-0777-P phosphatase activity and mass spectrometry-based quantification of ALPL.** A, The CS-0777-P phosphatase activity and ALPL amount for each fraction. The correlation coefficient between these was 0.9965. ALPL amount and CS-0777-P phosphatase activity are indicated by a solid line and a dashed line, respectively. B, Top 25 proteins demonstrating high correlation coefficient between CS-0777-P phosphatase activity and mass spectrometry-based quantitation among the identified 266 proteins. ALPL ranked 2nd place.

**Fig. 5. CS-0777-P phosphatase activity of recombinant proteins.** A, Specific CS-0777-P phosphatase activity of the recombinant proteins. Candidate proteins (ALPL, ALPI, ALPP, and ALPPL) and the negative control (EGFP) were expressed in the mammalian cell line, and the enzyme activity was tested. The recombinant proteins were quantified by Western blotting. The data are shown as the average of duplicates with error bars indicating the minimum and maximum values (n = 10052).

B, Specific CS-0777-P phosphatase activity of the recombinant proteins. Candidate proteins (LPP1, LPP2, LPP3, SPP1, and SPP2) and the negative control (EGFP) were expressed in the mammalian cell line, and the enzyme activity was tested. The recombinant proteins were quantified by GFP fluorescence. The data are shown as the average of duplicates with error bars representing the minimum and maximum values (n = 2).
ALPL-specific inhibitor, levamisole (36, 37) and immunodepletion using an anti-human ALPL antibody in the kidney extract.

To confirm the specificity of levamisole, we studied its effect on CS-0777-P phosphatase activity of recombinant ALP proteins, LPP1, and LPP3. Among these, levamisole prominently inhibited only CS-0777-P phosphatase activity of ALPL (supplemental Fig. S2). We then examined the effect of levamisole on CS-0777-P phosphatase or fingolimod-P phosphatase activity from the human kidney extract using specimen #5, which was used as a purification source. We found that levamisole inhibited CS-0777-P phosphatase activity in a concentration-dependent manner, and that 1 mM of levamisole inhibited ~80% of the activity in the extract. This indicated that ALPL, but no other ALPs or LPP proteins, was mainly responsible for the activity (Fig. 6A). On the other hand, 10 mM of levamisole inhibited ~30% of fingolimod-P phosphatase activity in the extract. This demonstrated that ALPL was not responsible for the majority of fingolimod-P phosphatase activity in human kidney extract (Fig. 6B).

Next, to confirm the general contribution of ALPL, the effect of levamisole was examined on the other human kidney specimens. More than 50% inhibition by 1 mM levamisole in all the tested samples (supplemental Fig. S3) suggested that ALPL was the major CS-0777-P phosphatase in humans.

As an independent confirmation, we further attempted immunodepletion experiments using an anti-human ALPL antibody. The human kidney extract was incubated with an anti-human ALPL monoclonal antibody or anti-mouse IgG as a negative control in the presence of protein G-agarose, and the immunodepleted samples were tested for CS-0777-P phosphatase activity. More than 80% of CS-0777-P phosphatase activity in the human kidney extract was immunodepleted with anti-human ALPL antibody (Fig. 7). We confirmed specificity of ALPL antibody by immunodepletion experiments toward recombinant ALPs and LPPs (supplemental Fig. S4). Although the activity of ALP and ALPPPL was removed about 20% by anti-ALP antibody, the expression of these ALP isozymes was very low in human kidney (data not shown), and thus, the decrease in CS-0777-P phosphatase activity would be due to the results of ALPL depletion from human kidney extract.

To estimate the contribution of the ALPL in vivo, we tested levamisole on human liver, lung and small intestine extracts or S9 fraction (the supernatant of tissue extract, see details under “Experimental Procedures”) (supplemental Fig. S5). Levamisole inhibited the dephosphorylation activity in the liver and lung, suggesting that the major enzyme in those tissues would be ALPL. We also examined levamisole on the dephosphorylation of CS-0777-P in vivo using rats to detect the inhibitory effect. Unfortunately, levamisole had little influence on the blood concentration of CS-0777 in rats after administration of CS-0777-P due to the insufficient exposure of levamisole even at the maximum tolerant dose (50 mg/kg s.c.).

Taken together, all of the data consistently support that ALPL is the major CS-0777-P phosphatase in human kidneys, whereas the contribution of other ALP proteins, LPP1 and LPP3 is low.

**DISCUSSION**

In this study, we have successfully purified and identified the primary phosphatase candidate responsible for dephosphorylation CS-0777-P in human kidneys by improved proteomic correlation profiling, an integration of traditional biochemistry and state-of-the-art proteomics technology.

The identified CS-0777-P phosphatase, ALPL, was clearly distinguishable from the reported fingolimod-P phosphatase, LPP3. In addition, we have revealed that ALPL is the major CS-0777-P phosphatase candidate for the human kidney, and that the contribution was estimated to be more than 80% based on the following three observations: 1) we observed a single broad active peak in all purification steps (Fig. 3); 2)
Moreover, human ALPs are membrane-bound enzymes (42). An approach was both time-consuming and labor-intensive. Activity by following a distinct band on the SDS-PAGE gel; such quantity and purity to enable its correlation with enzyme activity, the responsible protein had to be isolated at sufficient quantities. Solubilization is necessary before chromatography, the most common technique for protein purification. Indeed, in previous reports, ALPs were purified from very large amounts of starting materials, such as 500 g of human placentas with six steps (43), 21 g of human placenta with between seven to nine steps (44), or 1–3 kg of bovine kidney with six steps (45). In this study, ALPL was identified as the active enzyme from only a 200-fold purification of human kidney extract in this study, although we were not able to confirm the enzyme activity solely on the basis of correlation, as there were numerous other species on the band of the SDS-PAGE gel that correlated with the enzyme activity by this 4-step purification (supplemental Fig. S6).

We have demonstrated that the phosphatases of fingolimod-P and CS-0777-P were different enzymes. Given this observation, it is intriguing that identified kinases for fingolimod and CS-0777 were also different (6, 28). That different enzymes are responsible for catalyzing phosphorylation and de-phosphorylation of these related molecules could have important implications for drug metabolism, as each could thus be subject to distinct pharmacological effects (e.g. extensive metabolizer, poor metabolizer), and could be associated with different safety profiles and administration requirements (e.g. dosing). Indeed, the concentration of CS-0777-P, an active metabolite, in the phase I study of healthy volunteers was more than 20-fold higher than CS-0777 (26), whereas the concentration of fingolimod-P was about the same concentration of fingolimod (41), highlighting these metabolic differences. Thus, in addition to the selectivity, inefficient dephosphorylation of CS-0777-P could demonstrate a better pharmacological benefit than fingolimod-P. Although contributions of the other ALP isozymes in vivo need to be clarified, identification of CS-0777-P phosphatase in the kidney represents a critical first step to fully understand the pharmacokinetics and pharmacodynamics of CS-0777.

Purification of a biologically active protein from complex endogenous biological sources is a challenging task, usually requiring large amounts of samples and many separation steps. Traditionally, to identify an enzyme with some desired activity, the responsible protein had to be isolated at sufficient quantity and purity to enable its correlation with enzyme activity by following a distinct band on the SDS-PAGE gel; such an approach was both time-consuming and labor-intensive. Moreover, human ALPs are membrane-bound enzymes (42). Membrane proteins are known to be difficult to purify because solubilization is necessary before chromatography, the most common technique for protein purification. Indeed, in previous reports, ALPs were purified from very large amounts of starting materials, such as 500 g of human placentas with six steps (43), 21 g of human placenta with between seven to nine steps (44), or 1–3 kg of bovine kidney with six steps (45). In this study, ALPL was identified as the active enzyme from only about 1 g of human kidney with four purification steps, which clearly demonstrated the advantages of proteomic correlation profiling.

In proteomic correlation profiling, we first calculated each protein’s correlation coefficient between the enzyme activity profile and protein abundance profile determined by proteomics technology toward chromatography fractions. Then, we could select possible candidates for the enzyme among proteins with a high correlation value by domain predictions using informatics tools. By using this technology, we do not have to observe the separated bands correlating with enzyme activity; thereby, reducing the purification steps and starting materials because the required purity is much less than conventional approaches. Indeed, we could identify the ALPL as a candidate protein from only a 200-fold purification of human kidney extract in this study, although we were not able to confirm the enzyme activity solely on the basis of correlation, as there were numerous other species on the band of the SDS-PAGE gel that correlated with the enzyme activity by this 4-step purification (supplemental Fig. S6). Furthermore, we retrospectively applied proteomic correlation profiling in the third step fraction, anion exchange chromatography, and found that ALPL was identified as the highest ranked protein having a phosphatase domain while only one another protein had the domain. This indicated that we could have reduced one purification step further to identify ALPL (supplemental Fig. S7); however, there are limitations to this method. 1) If post-translational modification regulates an enzyme activity and the profile of the modified protein is different from that of the total protein, the method should not work because current proteomic correlation profiling is based on the profile of total proteins. 2) If there is an endogenous inhibitor protein in the fractions, the enzyme activity profile should not correlate with the simple protein amount of a single protein. 3) If more than one protein are responsible for the targeted enzyme activity and the profiles of those proteins are not separated in chromatography, again the enzyme activity profile should not correlate with the amount of a single protein. In addition, 4) if we cannot choose candidate proteins based on protein domain information, it is highly possible that we have too many candidates. In all cases above, adding additional purification steps and incorporating other sources of biological information could further reduce the list of candidates to a more manageable number.

In this study, we enhanced the protein correlation profiling approach from our previous study by incorporating label-free intensity-based protein quantitation as implemented in the recently developed MaxQuant software suite (33, 34, 38). We introduced a protein internal standard into each fraction to normalize for variations in sample complexity among fractions. It is noteworthy that this normalization strategy was critical for successful identification of the protein responsible for our desired activity. This is the first study using this technology for the enzyme class other than kinase, and moreover, the first example using one of the most complex and notorious protein mixtures, a tissue extract as a purification source. We believe that this approach can be further extended well beyond kinases and phosphatases to a wide variety of enzyme activities, and that this study in particular establishes a foundation for proteomic correlation profiling to be used as a general method.
Acknowledgments—We thank the National Disease Research Interchange and the Human Animal Bridging Research Organization for the provision of human kidney blocks. Dr. Yuji Ogura for experimental suggestions and data analysis, and Kosuke Asaba for the mass spectrometry experiments. We also appreciate Drs. Takashi Kagari, Takachi Shimozato, Kiyoko Yonesu, Futoshi Nara, Takashi Mochizuki, Edward Huttilin and Ms. Charmaine Yeoh for their critical reading of this manuscript.

References

1. Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Kawanabe, K., Fukushima, S., Yoshida, S., Kawaguchi, J., Fujita, Y., Ozeki, Y., Arai, H., Yoshimura, C., Furukawa, H., Haruyama, H., Ichikawa, K., Yamashita, M., Matsuoka, T., and Iijima, Y. (2004) Identification of a cytokine and its receptor by functional screening of the extracellular proteome. Science 302, 807–811

2. Lin, H., Lee, E., Hestir, K., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck, R., Wu, G., Zhou, A., Behrens, D., Hollenberg, D., Linnemann, T., Qin, M., Wong, J., Chu, K., Doberstein, S. K., and Williams, L. T. (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. FEBS Lett. 581, 1183–1196

3. Perocchi, F., Gehl, V. M., Girgis, H. S., Xiao, X., Xie, X., Mootha, V. K., and Mann, M. (2003) Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426, 570–574

4. Foster, L. J., Hoog, C. L., Zhang, Y., Xie, X., Mootha, V. K., and Mann, M. (2006) A mammalian organelle map by protein correlation profiling. Cell 125, 187–199

5. Kuromitsu, S., Yokota, H., Hiramoto, M., Yurt, M., Naitou, M., Nakamura, N., Kawai, S., Kobata, M., Kato, M., Furuchi, K., Mita, H., and Yamada, T. (2009) Combination of MS protein identification and bioassay of chromatographic fractions to identify biologically active substances from complex protein sources. Mol. Cell. Proteomics 8, 1318–1323

6. Compston, A., and Coles, A. (2008) Multiple sclerosis. Lancet 372, 1502–1517

7. Brinkmann, V., Billich, A., Baumann, T., Heining, P., Schmouder, R., Francis, G., Aradthy, S., and Burtin, P. (2010) FTY720: discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897

8. Ransohoff, R. M. (2007) Natalizumab for Multiple Sclerosis. N. Engl. J. Med. 356, 2622–2629

9. Galetta, S. L., and Markowitz, C. (2005) US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

CNS Drugs 19, 239–252

10. Kuromitsu, S., Yokota, H., Hiramoto, M., Naitou, M., Nakamura, N., Kawai, S., Kobata, M., Kato, M., Furuchi, K., Mita, H., and Yamada, T. (2009) Combination of MS protein identification and bioassay of chromatographic fractions to identify biologically active substances from complex protein sources. Mol. Cell. Proteomics 8, 1318–1323

11. Compston, A., and Coles, A. (2008) Multiple sclerosis. Lancet 372, 1502–1517

12. Brinkmann, V., Billich, A., Baumann, T., Heining, P., Schmouder, R., Francis, G., Aradthy, S., and Burtin, P. (2010) FTY720: discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897

13. Ransohoff, R. M. (2007) Natalizumab for Multiple Sclerosis. N. Engl. J. Med. 356, 2622–2629

14. Galetta, S. L., and Markowitz, C. (2005) US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

CNS Drugs 19, 239–252

15. Marsolais, D., and Rosen, H. (2009) Chemical modulars of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat. Rev. Drug Discov. 8, 297–307

16. Horga., A., Castillio., J., and Montalban. X. (2010) Fingolimod for relapsing multiple sclerosis: an update. Expert Opin. Pharmacother. 11, 1183–1196

17. Fujita, T., Hirose, Y., Toneta, M., Sasaki, S., Inoue, K., Ichii, M., Hirase, S., Chiba, K., Sakamoto, H., and Arita, M. (1996) Potent Immunomodulators, 2-Alkyldiaminoester, 1,3-diols. J. Med. Chem. 39, 4451–4459

18. Brinkmann, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001) FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 72, 764–769

19. Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O’Neill, S. L., Morris, M. A., Setlady, Y., Zhu, R., Zigler, M. A., Burch, T. L., Ley, K., Tung, K. S., Etana, M. G., Liu, J., McHaid, T. L., Pearson-White, S., and Lynch, K. R. (2005) Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280, 36865–36872

20. Zemann, B., Kinzel, B., Muller, M., Reuschl, R., Mechtcheriakova, D., Urz, N., Boromancin, F., Baumann, T., and Billich, A. (2006) Sphingosine kinase type 2 is essential for lymphopoeisis induced by the immunomodulatory drug FTY720. Blood 107, 1454–1458

21. Brinkmann, V., Davis, M. D., Harris, E. F., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumann, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453–21457

22. Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shi, G. J., Card, D., Keoheane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Alterations in lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346–349

23. Nishi, T., Miyazaki, S., Takemoto, T., Suzuki, K., Iio, Y., Nakajima, K., Ohnuki, T., Kawase, Y., Nara, F., Inaba, S., Izumi, T., Yuita, H., Oshina, K., Doi, H., Inoue, R., Tomisato, W., Kagari, T., and Shimozato, T. (2011) Discovery of CS-0777: A potent, selective, and orally active S1P1 agonist. ACS Med Chem Lett 2, 368–372

24. Sanna, G., Liao, J., Jo, E., Hono, C., Ahn, M. Y., Petersen, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., and Rosen, H. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte reirculation and heart rate. J. Biol. Chem. 279, 13839–13848

25. Moerby, J. B., Rohatagi, S., Zahir, H., Hsu, C., Novick, R. J., and Trutt, K. E. (2011) Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator. J. Clin. Pharmacol 51, 996–1006

26. Deleted in proof

27. Billich, A., Boromancin, F., Deyay, P., Mechtcheriakova, D., Urtz, N., and Baumann, T. (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278, 47408–47415

28. Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S., and Spiegel, S. (2002) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554, 189–193

29. Mechtcheriakova, D., Wlachos, A., Sobanov, J., Boromancin, F., Zlabinger, G., Baumann, T., and Billich, A. (2007) FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett. 581, 3063–3068

30. Wessel, D., and Flügge, U. I. (1984) A method for the quantitative recovery of protein in diluted solution in the presence of detergents and lipid. Anal. Biochem. 138, 141–143

31. Rappisibler, J., Ishihama, Y., and Mann, M. (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663–670

32. Cox, J., Martic, I., Hiliger, M., Nagaraj, N., Selbach, M., Olsen, J. V., and
Mann, M. (2009) A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 4, 698–705
34. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805
35. Kersey, P. J., Duarte, J., Williams, A., Karavidopoulou, Y., Birney, E., and Apweiler, R. (2004) The International Protein Index: An integrated database for proteomics experiments. Proteomics 4, 1985–1988
36. Martins, M. J., Negrão, M. R., and Hipólito-Reis, C. (2001) Alkaline phosphatase from rat liver and kidney is differentially modulated. Clin. Biochem. 34, 463–468
37. Kozlenkov, A., Le Du, M. H., Cuniasse, P., Ny, T., Hoylaerts, M. F., and Millán, J. L. (2004) Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase. J. Bone Miner. Res. 19, 1862–1872
38. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372
39. Sigal, Y. J., McDermott, M. I., and Morris, A. J. (2005) Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J. 387, 281–293
40. Le Stunff, H., Peterson, C., Thornton, R., Milstien, S., Mandala, S. M., and Spiegel, S. (2002) Characterization of murine sphingosine-1-phosphate phosphohydrolase. J. Biol. Chem. 277, 8920–8927
41. Kovarik, J. M., Dole, K., Riviere, G. J., Pommer, F., Maton, S., Jin, Y., Lasseter, K. C., and Schmouder, R. L. (2009) Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J. Clin. Pharmacol. 49, 212–218
42. Fishman, W. H. (1974) Perspectives on alkaline phosphatase isoenzymes. Am. J. Med. 56, 617–650
43. Ghosh, N. K., and Fishman, W. H. (1968) Purification and properties of molecular-weight variants of human placental alkaline phosphatase. Biochem. J. 108, 779–792
44. Doellgast, G. J., and Fishman, W. H. (1974) Purification of human placental alkaline phosphatase. Biochem. J. 141, 103–112
45. Cathala, G., and Brunel, C. (1975) Bovine kidney alkaline phosphatase. Purification, subunit structure, and metalloenzyme properties. J. Biol. Chem. 250, 6040–6045